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1. Introduction 35 
Nonalcoholic fatty liver disease (NAFLD) is a disease of increasing prevalence and 36 
has been recognized as a global public health problem, affecting approximately one third of 37 
the general adult population and one tenth of children [1,2]. The prevalence of NAFLD 38 
increases with obesity, type 2 diabetes mellitus (T2DM) and/or metabolic syndrome (MetS) 39 
[1,2]. NAFLD is now among the leading causes of cirrhosis [3], hepatocellular carcinoma [4] 40 
and liver transplantation [5]. Besides hepatic morbidity, NAFLD has been associated to extra-41 
hepatic morbidity too [6], including metabolic complications, chronic kidney, malignancies 42 
and cardiovascular disease (CVD), which all contribute to the higher mortality observed 43 
among NAFLD patients [7]. Specifically, evidence from recent studies strongly emphasizes 44 
the importance of assessing the global CVD risk in patients with NAFLD and that NAFLD 45 
might be both a marker and an early mediator of CVD. 46 
NAFLD encompasses a spectrum of phenotypes, ranging from nonalcoholic simple 47 
steatosis (SS), histologically defined as intrahepatic lipid accumulation with or without mild 48 
inflammation, to nonalcoholic steatohepatitis (NASH), characterized by the addition of 49 
hepatic necroinflammatory features and/or fibrosis, up to NASH-related cirrhosis and its 50 
complications, including hepatocellular carcinoma [8].  51 
The pathogenesis of NAFLD is multifactorial, since various factors (“hits”) 52 
contribute to its development and progression [9]. Genetic predisposition (e.g., 53 
polymorphisms of patatin-like phospholipase domain-containing protein (PNPLA3 gene) 54 
[10,11], lifestyle factors (e.g., lack of exercise, high fructose and saturated fat intake etc. 55 
[12]), insulin resistance (IR) [13], redox imbalance [14] and certain adipokines [15] are 56 
regarded as established “hits”, whereas other factors, including impaired innate and adaptive 57 
immunity [16], dysbiosis of the gut microbiota [17] and endocrine disruptors [18], have been 58 
linked with NAFLD, although further validation is needed. 59 
 “Metabolism, Clinical and Experimental” has recently published two studies 60 
advancing our knowledge in NAFLD, which are presented and commented hereby: one of 61 
them focuses on NAFLD association with MetS [19] and the other on NAFLD association 62 
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with different types of dyslipidemia [20]. A third study reporting on the long-term efficacy 63 
and safety of pioglitazone in NASH patients with T2DM [21], recently published in “Annals 64 
of Internal Medicine”, is also discussed herein. 65 
 66 
2. NAFLD and metabolic syndrome 67 
 Karajamaki et al. [19] analyzed a subset of data from a cohort study of a middle-aged 68 
Finnish population (Oulu Project Elucidating Risk of Atherosclerosis [OPERA] study), 69 
aiming to evaluate the dynamic interaction between NAFLD and MetS on left ventricular 70 
mass index (LVMI), a surrogate of left ventricular hypertrophy (LVH) and a predictor of 71 
cardiac morbidity and mortality in hypertensive patients, major cardiovascular events 72 
(coronary heart disease, stroke or death), as well as new incidence of T2DM. More 73 
specifically, Karajamaki et al. [19] divided the population at baseline (1991-1993; n=958) into 74 
four groups: a) coexistence of NAFLD and MetS (19%); b) NALFD without Mets (7%); c) 75 
MetS without NAFLD (17%); and d) neither NAFLD nor MetS (57%). After a mean follow-76 
up of 16.3 years, major cardiovascular events occurred in 30% (hazard ratio [HR]: 2.8; 95% 77 
CI: 1.9-3.9), 20% (HR: 1.7; 95% CI: 1.0-3.1), 22% (HR: 2.1; 95% CI: 1.4-3.1) and 12% 78 
(reference group), respectively. Interestingly, in a multivariate Cox regression model, MetS 79 
with and without NAFLD could predict the risk for cardiovascular events, whereas NAFLD 80 
without MetS could not. Change in LVMI was statistically more significant in groups with 81 
both NAFLD and MetS, and MetS without NAFLD. 82 
Regarding new cases of T2DM, the rates were 47% (NAFLD and MetS), 24% 83 
(NAFLD without MetS), 40% (MetS without NAFLD) and 19% (neither NAFLD nor MetS), 84 
being statistically higher in groups with both NAFLD and MetS, and MetS without NAFLD. 85 
Interestingly, in the subset of individuals without MetS at baseline, the incidence of MetS 86 
during the follow-up was higher in those with (71%) than without (48%) NAFLD. Another 87 
important observation of this study is that the unfavorable genotype of PNPLA3 gene 88 
polymorphism, which is strongly associated with the susceptibility and severity of NAFLD 89 
[10,11], was most prevalent in individuals with NAFLD without MetS. 90 
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 To the best of our knowledge, this is the first cohort study evaluating the combined 91 
effect of NAFLD and MetS on cardiovascular events and T2DM incidence. Although limited 92 
by the fact that OPERA was not specifically designed for this aim and by the small number of 93 
individuals in the NAFLD without MetS group (7%), this study indicates that NAFLD affects 94 
cardiovascular morbidity and T2DM incidence mainly when it is combined with MetS, 95 
thereby implying that IR may be the pathogenetic common denominator resulting in higher 96 
cardiovascular morbidity and not NAFLD itself. However, other investigators, also mentioned 97 
by the authors [19], reported that hypertensive patients with T2DM and with NAFLD exhibit 98 
a remarkably higher frequency of LVH than hypertensive diabetic patients without NAFLD, 99 
and that NAFLD is related with LVH independently of conventional cardiovascular risk 100 
factors and other potential co-founders [22]. Therefore, due to the limited number of 101 
individuals in the NAFLD without MetS group [19], further large-scale relative studies are 102 
warranted to elucidate the potential impact of NAFLD on cardiovascular morbidity and 103 
T2DM incidence when or not combined with MetS. Furthermore, this study strengthens 104 
existing evidence that PNPLA3 gene polymorphism predisposes to NAFLD, but not MetS or 105 
T2DM. In this regard, PNPLA3 gene polymorphism promotes advanced liver damage in 106 
NAFLD [10,11], increasing hepatic morbidity, but it is not associated with IR or T2DM [23], 107 
thereby not increasing NAFLD-related cardiovascular morbidity. This study also reinforces 108 
the concept that NALFD itself is able to favor the onset of MetS. Therefore, it could be 109 
speculated that, when NAFLD is not efficiently managed, it may foster the development of 110 
MetS and both of them jointly increase the risk of cardiovascular morbidity. However, this 111 
hypothesis should be confirmed by specifically designed future cohort studies. 112 
 113 
3. NAFLD and lipid profiles 114 
 Du et al. [20] performed a cross-sectional study in a large sample (n=9560) of adult 115 
Chinese seen for routine health check-up. Individuals with T2DM or other liver disease and 116 
those on lipid-lowering medications were excluded. Based on liver ultrasound examination, 117 
approximately 39% of them were diagnosed with NAFLD. Lipid abnormalities were defined 118 
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according to National Cholesterol Education Program/Adult Treatment Panel (ATP)-III 119 
guidelines [24] and were subdivided into five mutually exclusive categories: a) isolated 120 
hypercholesterolemia (high low-density lipoprotein cholesterol [LDL-C], normal 121 
triglycerides; 2.9%); b) isolated hypertriglyceridemia (high triglycerides, normal LDL-C and 122 
high-density lipoprotein cholesterol [HDL-C]; 13.7%) c) dyslipidemia of MetS (normal LDL-123 
C, low HDL-C, high triglycerides; 9.5%); d) combined hyperlipidemia (high LDL-C and high 124 
triglycerides; 2.0%); e) isolated low-HDL-C (low HDL-C, normal LDL-C and triglycerides; 125 
10.9%). Individuals with normolipemia (normal LDL-C, HDL-C and triglycerides; 61.0%) 126 
served as a reference group. 127 
 Within NAFLD patients, 3.2% had isolated hypercholesterolemia, 23.3% isolated 128 
hypertriglyceridemia, 17.7% MetS dyslipidemia, 3.8% combined hyperlipidemia, 10.2% 129 
isolated low HDL-C, whereas 41.8% had normolipemia, providing evidence for higher rates 130 
of lipid abnormalities in NAFLD. Inversely, all lipid abnormalities showed higher rates of 131 
NAFLD compared to individuals with normolipemia (reference group). More specifically, 132 
combined hyperlipidemia provided the higher rates (unadjusted odds ratio [OR]: 9.0; 95% CI 133 
6.4-12.7), followed by MetS dyslipidemia (unadjusted OR: 7.30; 95% CI: 6.2-8.5), isolated 134 
hypertriglyceridemia (unadjusted OR: 5.3; 95% CI: 4.7-6.1), isolated hypercholesterolemia 135 
(unadjusted OR: 2.1; 95% CI: 1.7-2.7) and isolated low HDL-C (unadjusted OR: 1.6; 95% CI: 136 
1.4-1.8). The association between lipid profiles and NAFLD remained robust after adjustment 137 
for potential co-founders for combined hyperlipidemia, MetS dyslipidemia and isolated 138 
hypertriglyceridemia, but not for isolated hypercholesterolemia and isolated low HDL-C [20]. 139 
 To the best of our knowledge, this is the largest study evaluating the association 140 
between NAFLD and different lipid profiles. Although it is limited by its observational 141 
nature, thereby failing to prove causality, and by the fact that lipoprotein (a) (Lp(a)), an 142 
independent predictor of cardiovascular risk [25], was not evaluated, this study strengthens 143 
our knowledge on the close relationship between NAFLD and lipid profile and its potential 144 
impact on CVD. Combined hyperlipidemia also appears to be a risk factor for CDV; high 145 
triglyceride levels are associated with increased CVD risk [26] and high LDL-C has now 146 
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largely replaced total cholesterol as a risk marker for CVD from a biologic, epidemiologic, 147 
and genetic standpoint [27]. Noteworthy, NAFLD remained independently associated with all 148 
lipid abnormalities characterized by high triglyceride levels, which is commonly observed in 149 
the setting of IR. This study warrants further research. A deeper insight into lipid profiles in 150 
patients with NASH, especially those with liver fibrosis who have the poorer prognosis [28], 151 
would be of importance, and might have therapeutic perspectives. Implementation of an 152 
aggressive therapeutic strategy for dyslipidemia with hypolipidemic agents, also mentioned 153 
by the authors [20], might mitigate the risk for CVD among NAFLD patients [29]. However, 154 
to-date, contrasting data are available on hypolipidemic treatment in NASH [25,30] but in the 155 
end nor omega-3, fibrates or statins clearly proved to be effective in improving the features of 156 
liver damage other than steatosis in NASH. On the other hand, another point needing 157 
clarification is the selection of medications to treat different lipid profiles specifically in 158 
NAFLD subjects. Statins proved to be safe in NAFLD, thereby toning down previous fear for 159 
statin use in patients with abnormal liver function tests, while it remains unknown how to 160 
treat NAFLD patients with isolated hypertriglyceridemia, MetS dyslipidemia and isolated 161 
high HDL-C. Until further studies elucidate this issue in specifically NAFLD populations, it 162 
is suggested that we follow the recommendations published for general population. 163 
 164 
4. NAFLD and pioglitazone 165 
Cusi et al. [21] performed a single-center, randomized placebo controlled trial (RCT; 166 
18 months) followed by a 18-month open-label extension (totally 36 months) evaluating the 167 
long-term safety and efficacy of pioglitazone (45 mg/d; added to a hypocaloric diet), a 168 
peroxisome proliferator activated receptor (PPAR)-γ ligand, in patients with diabetes or 169 
prediabetes and biopsy-proven NASH (n=101). Previous studies had already shown a 170 
favorable effect of pioglitazone on hepatic steatosis and lobular inflammation, whereas its 171 
effect on hepatic fibrosis remained unclear, as we recently summarized [31]. At month 18 172 
(end of RCT), more patients in the pioglitazone than in the placebo group (58% vs. 17%, 173 
respectively) achieved the primary outcome, being the reduction of at least 2 points in the 174 
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NAFLD activity score (NAS) in 2 histologic categories, without worsening of fibrosis [21]. 175 
Furthermore, resolution of NASH occurred in 51% of pioglitazone-treated patients vs. 19% of 176 
those receiving placebo. Regarding specific histological lesions, patients on pioglitazone 177 
improved hepatic steatosis, inflammation, ballooning and, notably, fibrosis more than those in 178 
placebo. Interestingly, progression of fibrosis occurred in less patients on pioglitazone (12%) 179 
than placebo (28%). As expected, pioglitazone improved hepatic, muscle and adipose tissue 180 
IR, liver function tests and circulating adiponectin. All 18-month metabolic and histological 181 
improvements persisted over 36 months of therapy (open-label extension). Although weight 182 
gain was greater with pioglitazone (mean 2.5 kg over placebo), the overall rate of adverse 183 
events did not differ between groups and no case of bladder cancer or osteoporotic fracture 184 
was observed in pioglitazone group [21]. 185 
This study confirms that long-term pioglitazone treatment in patients with NASH and 186 
T2DM or prediabetes is a safe and effective choice and, contrary to previous trials where 187 
discontinuation resulted in histological “rebound” [32], it shows for the first time that 188 
metabolic and histological improvements, including fibrosis, are maintained during long-term 189 
treatment with pioglitazone. Similarly to a previous open-label extension of a rosiglitazone 190 
trial in NASH [33], the Cusi et al. study did not show further histological improvement during 191 
the extension, a finding that should be cautiously interpreted, because of the open-label nature 192 
and relatively high drop-out rates at the end of the extension that possibly resulted in a 193 
relatively underpowered substudy. 194 
The pharmacological treatment of NASH remains an unmet medical need [34], but 195 
the study by Cusi et al.  [21] adds value by proposing the use of pioglitazone in subgroups of 196 
NASH patients with T2DM or prediabetes. However, candidates for pioglitazone treatment 197 
should be carefully selected because of its potentially adverse effect on CVD, osteoporosis 198 
and bladder cancer [31,35]. Notably, selective PPAR-γ modulators have been developed, 199 
including INT131 (formerly AMG131) [36]. INT131 is designed to exhibit strong efficacy, 200 
but less side effects compared to PPAR-γ full agonists, such as pioglitazone [36]. INT131 was 201 
well tolerated and improved glycated hemoglobin in T2DM patients vs. placebo in phase II 202 
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trials [37,38]. Less adverse effects, including edema, fluid retention and weight gain were 203 
observed compared with rosiglitazone [37] or pioglitazone [38]. Based on these observations, 204 
INT131 is one of the most promising candidates for clinical trials in NASH patients, along 205 
with other new compounds that are rapidly changing the landscape of the pharmacological 206 
treatment of NASH. Noteworthy, pioglitazone, simvastatin or a combination treatment may 207 
have synergistic effects by inhibiting different functions, such as inflammatory response and 208 
lipid regulation, by inhibiting the CD40-CD40L signaling pathway to suppress the formation 209 
of atherosclerosis, and reducing epicardial adipose tissue and plasma inflammatory markers in 210 
CVD and MetS patients [39,40]. Specifically, simvastatin, apart from exerting pleiotropic 211 
effects on the cardiovascular system, may improve the prognosis of NASH-related fibrosis by 212 
increasing the expression of endothelial nitric oxide synthase, decreasing the expression of 213 
inducible nitric oxide synthase, and inhibiting the activation of human hepatic stellate cells 214 
involved in liver fibrogenesis and carcinogenesis; a low simvastatin dose might have a role in 215 
preventing NAFLD and addition of simvastatin is associated with a survival benefit for 216 
patients with chronic liver disease [41-43].  217 
 218 
5. Closing remarks 219 
NAFLD is a complex disease with a growing prevalence and thus clinical importance 220 
affecting both hepatic and extra-hepatic morbidity and mortality. Despite the increasing 221 
prevalence of NAFLD, there is currently no definitive therapeutic modality, besides weight 222 
loss and exercise [34]. Both, weight loss and exercise, are difficult to achieve and sustain, 223 
which makes the need for pharmacological treatment of paramount importance [28]. In our 224 
opinion, a more holistic approach might probably lead to more efficient management. 225 
NAFLD is not a separate entity: it usually coexists with other components of MetS, including 226 
obesity, T2DM and various lipid abnormalities [20], but the cross-talk is probably bi-227 
directional, i.e., NAFLD affects and is affected by other metabolic co-morbidities [44]. For 228 
example, T2DM patients have higher prevalence of NAFLD [45], but also hepatic lipid 229 
accumulation in NAFLD impairs hepatic glucose and lipid metabolism, thereby increasing the 230 
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risk of T2DM and CVD [7]. Because of the multifactorial nature of the disease, a combined 231 
treatment, simultaneously targeting more than one pathogenetic “hit”, might represent a more 232 
realistic management, as we previously suggested [28]. It would be advisable to effectively 233 
manage all related comorbidities, i.e., T2DM, lipid abnormalities, arterial hypertension, with 234 
a diabetes-like approach [28,46], though the impact on liver damage of such approach is 235 
currently unknown and more studies are needed, which however are implicated by the need 236 
for repeat biopsies and high drop-out rates [47].  237 
Remarkably, due to its multifactorial nature, the same medications may not be 238 
suitable for all NAFLD patients. Du et al. showed the diversity of lipid abnormalities in 239 
NAFLD [20], possibly implying that the same hypolipidemic medications are not similarly 240 
effective in all NAFLD patients. Further, each NAFLD patient has a different genetic 241 
background and different related co-morbidities and, last but not least, each patient has a 242 
different time course of liver disease, often unpredictable. Therefore, beyond the search for 243 
the single, “magic bullet” medication, suitable for all NAFLD patients, research should be 244 
oriented to a more holistic approach and a more personalized management.   245 
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